Outlook Therapeutics, Inc. (OTLK)

6,98 -0,09 (-1,27%) Ab 01:10PM EDT. Markt geöffnet.

Outlook Therapeutics, Inc.

Building F
Suite 320 485 Route 1 South
Iselin, NJ 08852
United States
609 619 3990
https://www.outlooktherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 24

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ralph H. Thurman	Independent Executive Chairman	207,5k	N/A	1949
Mr. C. Russell Trenary III	President, CEO & Director	610,9k	N/A	1958
Mr. Lawrence A. Kenyon CPA	Executive VP, CFO, Treasurer, Company Secretary & Director	N/A	N/A	1966
Mr. Jeffrey Evanson	Chief Commercial Officer	451,17k	N/A	1969
Ms. Alicia Tozier	Senior Vice President, Marketing & Market Access	N/A	N/A	N/A
Mr. Joel Prieve	Senior Vice President of Licensing and M&A	N/A	N/A	N/A
Dr. Surendra Sharma M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A
Dr. Jennifer M. Kissner Ph.D.	Senior Vice President of Clinical Development & Regulatory Affairs	N/A	N/A	N/A
Mr. Jedd Comiskey	Senior VP - Head of Europe	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Corporate Governance

Outlook Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.